TY - JOUR
KW - California
KW - Female
KW - Humans
KW - Male
KW - Mass Screening/methods/standards
KW - Middle Aged
KW - Primary Health Care/methods
KW - Psychometrics
KW - Reproducibility of Results
KW - Sensitivity and Specificity
KW - Substance Abuse Detection/methods/standards
KW - Substance-Related Disorders/diagnosis
KW - Surveys and Questionnaires
KW - Veterans/statistics & numerical data
KW - Drug use disorder
KW - primary care
KW - Screening test
KW - validation
AU - Q. Q. Tiet
AU - Y. E. Leyva
AU - R. H. Moos
AU - B. Smith
A1 - 
AB - OBJECTIVE: Drug use is prevalent and costly to society, but individuals with drug use disorders (DUDs) are under-diagnosed and under-treated, particularly in primary care (PC) settings. Drug screening instruments have been developed to identify patients with DUDs and facilitate treatment. The Drug Abuse Screening Test (DAST) is one of the most well-known drug screening instruments. However, similar to many such instruments, it is too long for routine use in busy PC settings. This study developed and validated a briefer and more practical DAST for busy PC settings. METHOD: We recruited 1300 PC patients in two Department of Veterans Affairs (VA) clinics. Participants responded to a structured diagnostic interview. We randomly selected half of the sample to develop and the other half to validate the new instrument. We employed signal detection techniques to select the best DAST items to identify DUDs (based on the MINI) and negative consequences of drug use (measured by the Inventory of Drug Use Consequences). Performance indicators were calculated. RESULTS: The two-item DAST (DAST-2) was 97% sensitive and 91% specific for DUDs in the development sample and 95% sensitive and 89% specific in the validation sample. It was highly sensitive and specific for DUD and negative consequences of drug use in subgroups of patients, including gender, age, race/ethnicity, marital status, educational level, and posttraumatic stress disorder status. CONCLUSIONS: The DAST-2 is an appropriate drug screening instrument for routine use in PC settings in the VA and may be applicable in broader range of PC clinics.
AD - VA Palo Alto Health Care System, Palo Alto, CA, United States; Stanford University School of Medicine, Stanford, CA, United States; California School of Professional Psychology at Alliant International University, San Francisco, CA, United States. Electronic address: quyen.tiet@va.gov.; VA Palo Alto Health Care System, Palo Alto, CA, United States.; VA Palo Alto Health Care System, Palo Alto, CA, United States; Stanford University School of Medicine, Stanford, CA, United States.; VA Palo Alto Health Care System, Palo Alto, CA, United States.
BT - Addictive Behaviors
C5 - Measures; Opioids & Substance Use
CY - England
JF - Addictive Behaviors
M1 - Journal Article
N2 - OBJECTIVE: Drug use is prevalent and costly to society, but individuals with drug use disorders (DUDs) are under-diagnosed and under-treated, particularly in primary care (PC) settings. Drug screening instruments have been developed to identify patients with DUDs and facilitate treatment. The Drug Abuse Screening Test (DAST) is one of the most well-known drug screening instruments. However, similar to many such instruments, it is too long for routine use in busy PC settings. This study developed and validated a briefer and more practical DAST for busy PC settings. METHOD: We recruited 1300 PC patients in two Department of Veterans Affairs (VA) clinics. Participants responded to a structured diagnostic interview. We randomly selected half of the sample to develop and the other half to validate the new instrument. We employed signal detection techniques to select the best DAST items to identify DUDs (based on the MINI) and negative consequences of drug use (measured by the Inventory of Drug Use Consequences). Performance indicators were calculated. RESULTS: The two-item DAST (DAST-2) was 97% sensitive and 91% specific for DUDs in the development sample and 95% sensitive and 89% specific in the validation sample. It was highly sensitive and specific for DUD and negative consequences of drug use in subgroups of patients, including gender, age, race/ethnicity, marital status, educational level, and posttraumatic stress disorder status. CONCLUSIONS: The DAST-2 is an appropriate drug screening instrument for routine use in PC settings in the VA and may be applicable in broader range of PC clinics.
PP - England
PY - 2017
SN - 1873-6327; 0306-4603
SP - 112
EP - 117
EP - 
T1 - Diagnostic accuracy of a two-item Drug Abuse Screening Test (DAST-2)
T2 - Addictive Behaviors
TI - Diagnostic accuracy of a two-item Drug Abuse Screening Test (DAST-2)
U1 - Measures; Opioids & Substance Use
U2 - 28609724
VL - 74
VO - 1873-6327; 0306-4603
Y1 - 2017
Y2 - Nov
ER -